Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation

Molecular Pharmacology

Volumn 78, Issue 3, 2010, Pages 384-393

  Warrener, Robyn ^a   Chia, KeeMing ^a   Warren, William D ^b   Brooks, Kelly ^a   Gabrielli, Brian ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1ALPHA; HETEROCHROMATIN PROTEIN 1BETA; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H3 LYSINE 9; SUBEROYLBISHYDROXAMIC ACID; UNCLASSIFIED DRUG; HETEROCHROMATIN; HETEROCHROMATIN-SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP-1; HISTONE; HISTONE DEACETYLASE; LYSINE; NONHISTONE PROTEIN;

ACETYLATION; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL SYNCHRONIZATION; CHROMOSOME; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; EMBRYO; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; MAMMAL CELL; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN METHYLATION; ANIMAL; ANIMAL EMBRYO; EMBRYOLOGY; FEMALE; HELA CELL LINE; HETEROCHROMATIN; METABOLISM; METHYLATION; MITOSIS; PROTEIN PROCESSING; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DROSOPHILA MELANOGASTER; EMBRYO, NONMAMMALIAN; FEMALE; HELA CELLS; HETEROCHROMATIN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; LYSINE; METHYLATION; MITOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 77956255304     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.062976     Document Type: Article

References (48)

1. Aoyagi S and Archer TK (2005) Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 15:565-567.
2. Archer SY, Meng S, Shei A, and Hodin RA (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95:6791-6796.
3. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, and Kouzarides T (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410:120-124.
4. Bernhard D, Skvortsov S, Tinhofer I, Hübl H, Greil R, Csordas A, and Kofler R (2001) Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ 8:1014-1021.
5. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, and Bates SE (2002) Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1:937-941.
6. Bolden JE, Peart MJ, and Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784.
7. Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, and Saunders NA (2001) Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem 276:22491-22499.
8. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, and Gabrielli B (2004) Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 23:6693-6701.
9. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG, and Gabrielli BG (2001) Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60:828-837.
10. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, et al. (2009) Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 15:840-850.
11. Choi E, Choe H, Min J, Choi JY, Kim J, and Lee H (2009) BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. EMBO J 28:2077-2089.
12. Cimini D, Mattiuzzo M, Torosantucci L, and Degrassi F (2003) Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 14:3821-3833.
13. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, and Helin K (2006) The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442:307-311.
14. Dai J, Sullivan BA, and Higgins JM (2006) Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Dev Cell 11:741-750.
15. De Boer L, Oakes V, Beamish H, Giles N, Stevens F, Somodevilla-Torres M, Desouza C, and Gabrielli B (2008) Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene 27:4261-4268.
16. Dillon N and Festenstein R (2002) Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet 18:252-258.
17. Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, and Kao GD (2005) Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther 4:197-206.
18. Eissenberg JC and Elgin SC (2000) The HP1 protein family: getting a grip on chromatin. Curr Opin Genet Dev 10:204-210.
19. Eot-Houllier G, Fulcrand G, Watanabe Y, Magnaghi-Jaulin L, and Jaulin C (2008) Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesion. Genes Dev 22:2639-2644.
20. Fischle W, Tseng BS, Dormann HL, Ueberheide BM, Garcia BA, Shabanowitz J, Hunt DF, Funabiki H, and Allis CD (2005) Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature 438:1116-1122.
21. Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G, and Jenuwein T (2006) Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev 20:1557-1562.
22. Foe V, Odell GM, and Edgar BA, eds (1993) Mitosis and Morphogenesis in the Drosophila Embryo: Point and Counterpoint, Cold Spring Harbor Laboratory Press, New York.
23. Gabrielli B, Warrener R, Burgess A, and Beamish H (2004) Defining the chemotherapeutic targets of histone deacetylase inhibitors. Ann NY Acad Sci 1030:627-635. (Pubitemid 40378962)
24. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, and Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
25. Hayakawa T, Haraguchi T, Masumoto H, and Hiraoka Y (2003) Cell cycle behavior of human HP1 subtypes: distinct molecular domains of HP1 are required for their centromeric localization during interphase and metaphase. J Cell Sci 116:3327-3338.
26. Hirota T, Lipp JJ, Toh BH, and Peters JM (2005) Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 438: 1176-1180.
27. Ishii S, Kurasawa Y, Wong J, and Yu-Lee LY (2008) Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci USA 105:4179-4184.
28. Jansen LE, Black BE, Foltz DR, and Cleveland DW (2007) Propagation of centromeric chromatin requires exit from mitosis. J Cell Biol 176:795-805.
29. Lindemann RK, Gabrielli B, and Johnstone RW (2004) Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779-788.
30. Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, and Jaulin C (2007) Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 67:6360-6367.
31. Nakayama J, Rice JC, Strahl BD, Allis CD, and Grewal SI (2001) Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292:110-113.
32. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, and Turner BM (2007) Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 282:4408-4416.
33. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, and Johnstone RW (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:3697-3702.
34. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, and Johnstone RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63:4460-4471.
35. Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schöfer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, et al. (2001) Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107:323-337.
36. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, and Gabrielli BG (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11:2069-2083.
37. Robbins AR, Jablonski SA, Yen TJ, Yoda K, Robey R, Bates SE, and Sackett DL (2005) Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4:717-726.
38. Schmiedeberg L, Weisshart K, Diekmann S, Meyer Zu Hoerste G, and Hemmerich P (2004) High- and low-mobility populations of HP1 in heterochromatin of mammalian cells. Mol Biol Cell 15:2819-2833.
39. Stevens FE, Beamish H, Warrener R, and Gabrielli B (2008) Histone deacetylase inhibitors induce mitotic slippage. Oncogene 27:1345-1354.
40. Stewart MD, Sommerville J, and Wong J (2006) Dynamic regulation of histone modifications in Xenopus oocytes through histone exchange. Mol Cell Biol 26: 6890-6901.
41. Subramanian C, Opipari AW, Jr., Bian X, Castle VP, and Kwok RP (2005) Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:4842-4847.
42. Taddei A, Maison C, Roche D, and Almouzni G (2001) Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol 3:114-120.
43. Taddei A, Roche D, Bickmore WA, and Almouzni G (2005) The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6:520-524.
44. Taddei A, Roche D, Sibarita JB, Turner BM, and Almouzni G (1999) Duplication and maintenance of heterochromatin domains. J Cell Biol 147:1153-1166.
45. Tyler JK, Adams CR, Chen SR, Kobayashi R, Kamakaka RT, and Kadonaga JT (1999) The RCAF complex mediates chromatin assembly during DNA replication and repair. Nature 402:555-560.
46. Vader G and Lens SM (2008) The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 1786:60-72.
47. Wang X and Dai W (2005) Shugoshin, a guardian for sister chromatid segregation. Exp Cell Res 310:1-9.
48. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, and Gabrielli B (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17:1550-1552.